102 citations
,
October 2010 in “Molecular Pharmaceutics” Copper-doxorubicin nanoparticles effectively treat tumors with less toxicity.
August 2024 in “Dermatology and Therapy” Vorasidenib can cause unusual hair growth.
6 citations
,
December 2021 in “Journal of Cancer Research and Therapeutics” The treatment improved survival and controlled cancer spread but required managing side effects like rashes.
1 citations
,
May 2025 in “The Journal of Rheumatology” Upadacitinib may help treat difficult cases of systemic lupus erythematosus.
Vismodegib effectively treats advanced basal cell carcinoma but requires careful management of serious side effects.
35 citations
,
May 2008 in “Journal of Clinical Oncology” A cancer patient died from a severe skin reaction after taking the drug cetuximab.
82 citations
,
March 2013 in “PLoS ONE” Vemurafenib causes skin side effects similar to RASopathies, requiring regular skin checks and UVA protection.
18 citations
,
May 2013 in “Cutaneous and Ocular Toxicology” The cancer drugs bortezomib and lenalidomide cause skin side effects in many patients.
May 2017 in “Journal of The American Academy of Dermatology” An intact skin barrier is crucial to prevent infection in cases of tether-induced tenosynovitis.
1 citations
,
December 2012 in “Journal of dermatological science” Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.
New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.
September 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib improves anxiety and depression in severe alopecia areata patients.
1 citations
,
October 2014 in “Annals of oncology” Paclitaxel and nab-paclitaxel can be safe and effective for advanced gastric cancer patients on hemodialysis.
12 citations
,
January 2014 in “Journal of international medical research” Pemetrexed is as effective as docetaxel but has fewer side effects for treating nonsmall-cell lung cancer after EGFR-TKI therapy failure.
1461 citations
,
March 2004 in “Annals of oncology” Pegylated liposomal doxorubicin is as effective as conventional doxorubicin but causes fewer heart problems and side effects.
12 citations
,
January 2018 in “Breast Cancer Basic and Clinical Research” Subcutaneous trastuzumab improves some symptoms and doesn't harm overall quality of life in breast cancer patients.
14 citations
,
November 2024 in “Pharmaceuticals” Spanlastic nano-vesicles improve famotidine's effectiveness and absorption.
Finasteride may improve prostate cancer therapy by enhancing testosterone's benefits and reducing risks.
36 citations
,
June 2014 in “Experimental Neurology” Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
52 citations
,
May 1993 in “Southern Medical Journal” Imuvert can prevent some chemotherapy-induced hair loss.
4 citations
,
March 2008 in “Journal of the American Academy of Dermatology”
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.
1 citations
,
December 2021 in “JAAD case reports” A woman with severe hair loss saw significant hair regrowth after adding platelet-rich plasma injections to her treatment with tofacitinib.
DOPE:DOPC liposomes can improve targeted cancer drug delivery, reducing side effects and increasing effectiveness.
March 2008 in “Aging health” Docetaxel is safe and works well for older people with cancer, with manageable side effects.
12 citations
,
September 2015 in “Drug Design Development and Therapy” AD198 is more effective than doxorubicin in stopping certain dog cancer cells.
July 2024 in “Journal of Investigative Dermatology” INTASYL is a promising, adaptable RNAi technology for treating skin cancers.
74 citations
,
February 2018 in “Journal of the American Academy of Dermatology” September 2020 in “Scientific periodicals of Ukraine” "Flosin – Prostamol Uno" effectively manages BPH symptoms with fewer side effects.
2 citations
,
January 2025 in “Сибирский научный медицинский журнал” TS-13 effectively stops tumor growth and reduces chemotherapy side effects.